With our leading COVID-19 vaccine candidate SCB-2019 (CpG 1018/Alum), we expect to commercialize one of the first protein-based COVID-19 vaccines enabling us to potentially help address the global shortage of COVID-19 vaccines.
The Trimer-Tag™ technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets.
Clover’s Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern
Clover Appoints LiongHo Chua as President of Greater China
Clover’s Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious Disease
Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022